Limited-sampling strategies for anidulafungin in critically ill patients (original) (raw)
Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections
Eleonora Swart
Antimicrobial Agents and Chemotherapy, 2017
View PDFchevron_right
Low but Sufficient Anidulafungin Exposure in Critically Ill Patients
J. Kosterink
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis
Gabriele Sganga
International Journal of Antimicrobial Agents, 2012
View PDFchevron_right
Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia
David Kong
International journal of antimicrobial agents, 2014
View PDFchevron_right
Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration
María-José Giménez
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis
J. Kosterink
Antimicrobial Agents and Chemotherapy, 2017
View PDFchevron_right
Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis
Lei Ma
Antimicrobial Agents and Chemotherapy, 2006
View PDFchevron_right
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration
Florian Thalhammer
Journal of Antimicrobial Chemotherapy, 2011
View PDFchevron_right
Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review
Mahipal Sinnollareddy
International Journal of Antimicrobial Agents
View PDFchevron_right
Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients
Yan Yan
Acta pharmacologica Sinica, 2018
View PDFchevron_right
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
Vijay Yeldandi
Critical Care, 2009
View PDFchevron_right
Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration
David Navarro
The Journal of antimicrobial chemotherapy, 2014
View PDFchevron_right
Austrian Clinical Practice with Anidulafungin in 2008: A Multicenter Survey
M. Hell
Journal of Chemotherapy, 2011
View PDFchevron_right
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
Claude Martin
Critical Care, 2015
View PDFchevron_right
Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
I. Grigoras
Critical Care, 2011
View PDFchevron_right
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
Fabianne Carlesse
Pediatric Infectious Disease Journal, 2020
View PDFchevron_right
Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
L. Kovanda
Antimicrobial Agents and Chemotherapy, 2011
View PDFchevron_right
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
JIN WOONG SUH
Mycopathologia, 2020
View PDFchevron_right
Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling
John Bacher
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
A bedside scoring system (???Candida score???) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization
Pedro Saavedra
Critical Care Medicine, 2006
View PDFchevron_right
Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia
Lai-Chu See
Journal of Microbiology, Immunology and Infection, 2014
View PDFchevron_right
Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study
Jesús Gomez
Critical care medicine, 2017
View PDFchevron_right
Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients
J. Kosterink
Antimicrobial Agents and Chemotherapy, 2021
View PDFchevron_right
Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration
J. Belda
International journal of antimicrobial agents, 2017
View PDFchevron_right
Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia
G. Raponi
Journal of Chemotherapy, 2010
View PDFchevron_right